9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis J Clin Oncol 21(22):4151-6
2. 2011 Lessons From ASH 2010: A Focus on NHL J Natl Compr Canc Netw 9(1):7-11
3. 2010 Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma Blood 116(23):4934-7
4. 2010 An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma J Natl Compr Canc Netw 8(3):347-52
5. 2010 NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas J Natl Compr Canc Netw 8(3):288-334
6. 2010 A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Br J Cancer 103(12):1783-7
7. 2010 Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma Ann Oncol 21(1):133-9
8. 2010 High-dose chemo-radiotherapy for relapsed or refractory hodgkin lymphoma and the significance of pre-transplant functional imaging Br J Haematol
9. 2010 Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience Ann Oncol 21(3):574-81
10. 2010 Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes Clin Cancer Res 16(2):719-26
11. 2010 Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma J Clin Oncol 28(11):1896-903
12. 2009 Follicular lymphoma in the United States: first report of the national LymphoCare study J Clin Oncol 27(8):1202-8
13. 2009 Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial Br J Haematol 145(1):34-9
14. 2009 Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Br J Haematol
15. 2009 Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation Biol Blood Marrow Transplant 15(12):1538-42
16. 2009 Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma Br J Haematol 146(2):158-63
17. 2009 Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses J Clin Oncol 27(4):491-7
18. 2009 NCCN task force report: molecular markers in leukemias and lymphomas J Natl Compr Canc Netw 7 Suppl 4(S1-34, quiz S5-6
19. 2009 Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 J Clin Oncol
20. 2009 Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies J Clin Oncol
21. 2009 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood 113(20):4834-40
22. 2009 The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma Bone Marrow Transplant 43(12):941-8
23. 2008 Lymphoid malignancies: a decade and a half of dramatic improvements in outcome Clin Lymphoma Myeloma 8 Suppl 4(S126-7
24. 2008 A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma Br J Haematol 143(2):201-9
25. 2008 Synchronous presentation of systemic and brain non-Hodgkin lymphoma Leuk Lymphoma 49(12):2370-3
26. 2008 Non-Hodgkin's lymphomas J Natl Compr Canc Netw 6(4):356-421
27. 2008 Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity J Clin Oncol 26(11):1858-64
28. 2008 Hodgkin disease/lymphoma J Natl Compr Canc Netw 6(6):594-622
29. 2008 Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network J Clin Oncol 26(31):5107-12
30. 2008 Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma Clin Adv Hematol Oncol 6(6):437-45
31. 2008 Treatment of follicular lymphoma: current status Leuk Lymphoma 49 Suppl 1(7-17
32. 2008 Overview of lymphoma diagnosis and management Radiol Clin North Am 46(2):175-98, vii
33. 2007 NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer J Natl Compr Canc Netw 5 Suppl 1(S1-S22; quiz S3-2
34. 2007 Will radioimmunotherapy survive? Clin Adv Hematol Oncol 5(10):782-4
35. 2007 Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma Cancer 110(11):2528-34
36. 2007 Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression Cytogenet Genome Res 118(2-4):337-44
37. 2007 Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma Br J Haematol 139(3):425-8
38. 2007 Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine Leuk Lymphoma 48(3):521-5
39. 2007 Automated matching and segmentation of lymphoma on serial CT examinations Med Phys 34(1):55-62
40. 2007 FDG-PET lymphoma demonstration project invitational workshop Acad Radiol 14(3):330-9
41. 2007 Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann Oncol 18(11):1842-50
42. 2007 Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 Ann Oncol 18(6):1071-9
43. 2006 Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia J Clin Oncol 24(10):1575-81
44. 2006 Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population Ann Oncol 17(6):909-13
45. 2006 Hodgkin disease/lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4(3):210-30
46. 2006 Marker-controlled watershed for lymphoma segmentation in sequential CT images Med Phys 33(7):2452-60
47. 2006 Mantle cell lymphoma: an update on management Ann Oncol 17 Suppl 4(iv12-4
48. 2006 Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4(3):258-310
49. 2006 Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma Br J Haematol 134(2):202-7
50. 2006 Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas Blood 107(6):2477-85
51. 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24(1):166-73
52. 2005 Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL Blood 106(10):3383-5
53. 2005 Proteasome inhibitors in non-Hodgkin's lymphoma J Natl Compr Canc Netw 3 Suppl 1(S34-6
54. 2005 Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma Leuk Lymphoma 46(11):1569-73
55. 2005 Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23(4):676-84
56. 2005 Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy J Clin Oncol 23(16):3768-72
57. 2005 Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography J Clin Oncol 23(21):4652-61
58. 2005 Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999 Br J Haematol 130(5):691-9
59. 2005 R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy Leuk Lymphoma 46(4):541-7
60. 2005 Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23(30):7565-73
61. 2005 Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab Blood 105(12):4576-82
62. 2004 Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease Br J Haematol 124(5):645-52
63. 2004 The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide Ann Oncol 15(10):1495-503
64. 2004 Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease Br J Haematol 125(6):701-8
65. 2004 Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II J Natl Compr Canc Netw 2 Suppl 4(S21-2
66. 2004 The radioisotope contributes significantly to the activity of radioimmunotherapy Clin Cancer Res 10(23):7792-8
67. 2004 Non-Hodgkin's lymphoma clinical practice guidelines J Natl Compr Canc Netw 2(4):286-336
68. 2004 Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas Blood 103(5):1862-8
69. 2004 Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma Appl Immunohistochem Mol Morphol 12(3):211-5
70. 2004 Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103(10):3684-8
71. 2004 Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 104(12):3483-9
72. 2003 CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas Leuk Lymphoma 44(6):967-71
73. 2003 Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response J Nucl Med 44(2):260-8
74. 2003 MUC-1 mucin protein expression in B-cell lymphomas Appl Immunohistochem Mol Morphol 11(1):28-32
75. 2003 Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression Leuk Lymphoma 44(6):1027-35
76. 2003 Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma Cancer 98(6):1196-205
77. 2003 Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma Bone Marrow Transplant 32(7):673-9
78. 2003 Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood 102(6):1989-96
79. 2003 Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma Oncology (Williston Park) 17(11 Suppl 11):21-6
80. 2003 A clinical and scientific overview of tositumomab and iodine I 131 tositumomab Semin Oncol 30(2 Suppl 4):22-30
81. 2003 Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma Ann Oncol 14 Suppl 1(i5-10
82. 2002 Vaccination with CD20 peptides induces a biologically active, specific immune response in mice Blood 99(10):3748-55
83. 2002 Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma Blood 99(7):2554-61
84. 2002 Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma Genes Chromosomes Cancer 35(4):318-28
85. 2002 Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases Am J Surg Pathol 26(2):216-24
86. 2002 Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation Cancer J 8(5):371-6
87. 2001 Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol Blood 97(7):1929-36
88. 2001 Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma Leuk Lymphoma 40(3-4):419-23
89. 2001 Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma Leuk Lymphoma 42(5):1015-22
90. 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19(2):389-97
91. 2001 Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19(19):3918-28
92. 2001 Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas Oncogene 20(52):7686-93
93. 2001 NCCN: Non-Hodgkin's lymphoma Cancer Control 8(6 Suppl 2):102-13
94. 2001 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Blood 97(3):616-23
95. 2000 A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22 Eur J Haematol 64(2):104-13
96. 2000 Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18(6):1316-23
97. 2000 Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 14(9):1577-82
98. 2000 Cloning and characterization of a Golgin-related gene from the large-scale polymorphism linked to the PML gene Genomics 70(3):364-74
99. 2000 High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood 96(7):2399-404
100. 2000 Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure Ann Oncol 11 Suppl 1(75-80
101. 2000 Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy Leuk Lymphoma 39(1-2):67-75
102. 2000 Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22 Cytogenet Cell Genet 88(1-2):22-4
103. 2000 MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma Blood 95(9):2930-6
104. 1999 Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 17(12):3776-85
105. 1999 The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma Bone Marrow Transplant 23(6):561-7
106. 1999 Radioimmunotherapy for lymphoma Curr Opin Oncol 11(5):375-80
107. 1999 The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit Blood 94(8):2658-66
108. 1998 Emerging role of laparoscopy in the diagnosis of lymphoma J Clin Oncol 16(5):1909-15
109. 1998 Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma Clin Cancer Res 4(2):311-6
110. 1998 Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc Natl Acad Sci U S A 95(1):162-6
111. 1997 Microsatellite instability in breast cancer Ann Surg Oncol 4(4):310-5
112. 1997 Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas Clin Cancer Res 3(2):169-77
113. 1996 The AML1/ETO fusion protein activates transcription of BCL-2 Proc Natl Acad Sci U S A 93(24):14059-64
114. 1996 Derivation and characterization of retinoid-resistant human embryonal carcinoma cells Differentiation 60(4):251-7
115. 1995 BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma Leuk Lymphoma 20(1-2):85-9
116. 1995 The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism Genomics 26(2):327-33
117. 1995 The Wsh and Ph mutations affect the c-kit expression profile: c-kit misexpression in embryogenesis impairs melanogenesis in Wsh and Ph mutant mice Proc Natl Acad Sci U S A 92(9):3754-8
118. 1995 A novel L23-related gene 40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal and adult human tissues Hum Mol Genet 4(9):1499-507
119. 1995 Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma N Engl J Med 333(11):728-9; author reply 30
120. 1993 Mucosa-associated lymphoid-tissue lymphoma N Engl J Med 329(22):1657
121. 1993 Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia Am J Pathol 143(5):1301-11
122. 1993 A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma Genes Chromosomes Cancer 6(3):140-50
123. 1993 W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis Development 118(3):705-17
124. 1992 BCL2 oncogene translocation is mediated by a chi-like consensus J Exp Med 175(6):1575-88
125. 1992 Construction of complex directional complementary DNA libraries in SfiI Methods Enzymol 216(517-30
126. 1992 Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire Mol Immunol 29(2):193-203
127. 1992 Antigen selection in human lymphomagenesis Cancer Res 52(19 Suppl):5547s-51s
128. 1992 Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection J Exp Med 176(4):1137-48
129. 1991 Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell J Exp Med 173(1):197-207
130. 1991 Follicular lymphoma: a model of lymphoid tumor progression in man Ann Oncol 2 Suppl 2(115-22
131. 1991 Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis Blood 78(6):1552-60
132. 1991 Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy Blood 78(10):2768-72
133. 1990 Directional cloning of cDNA using a selectable SfiI cassette Gene 89(1):123-7
134. 1990 Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin Blood 76(11):2411-7
135. 1987 Regulation of ribosome synthesis during compensatory renal hypertrophy in mice Am J Physiol 253(4 Pt 1):C506-13
136. 1981 Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus Cell 24(2):531-41
137. 1980 Transformation by subgenomic fragments of Rous sarcoma virus DNA Cell 19(4):863-70
138. 1980 Transformation of NIH-3T3 mouse cells by avian retroviral DNAs Cold Spring Harb Symp Quant Biol 44 Pt 2(1169-76
139. 1979 Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus Cell 17(4):993-1002
140. 1978 gltB gene and regulation of nitrogen metabolism by glutamine synthetase in Escherichia coli J Bacteriol 133(1):139-48
141. 1976 Circadian periodicity of epidermal growth factor and its abolition by superior cervical ganglionectomy Endocrinology 99(6):1589-96


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.